James Luke Godwin, MD | Authors


PD-1 Checkpoint Inhibitors in Pretreated Non-Small Cell Lung Cancer

November 04, 2016

An overview of the data and rationale that led to the approval of nivolumab and pembrolizumab for NSCLC, with an emphasis on specific patient populations likely to benefit from this approach and future directions for clinical research in this area.